软组织肉瘤靶向治疗药物的研究进展

Advances in targeted therapeutic drugs of soft tissue sarcoma

软组织肉瘤组织学分型多,发病率低,但危害大。目前软组织肉瘤最常用的治疗方法是手术切除、放疗及化疗。很多软组织肉瘤患者确诊时已经是晚期,丧失了手术条件却又难以耐受化疗,严重降低了患者的生存质量。随着分子生物学的发展和靶向药物的出现,靶向药物在个体化治疗的疗效和安全性方面有显著的优势,其可延长患者的无进展生存期并提高患者的生命质量,为晚期不能耐受手术和化疗的软组织肉瘤患者提供了更多的治疗选择。目前软组织肉瘤常用的靶向药物有两类,一类是小分子化合物,包括安罗替尼、阿帕替尼和帕唑帕尼等;另一类是单克隆抗体,如贝伐珠单抗和PD-1抗体等。该文对靶向药物在软组织肉瘤中的治疗研究进展作一综述。

Soft tissue sarcomas have more histological types and lower incidence but cause great harm.At present,the most common treatments of soft tissue sarcomas are surgical resection,radiotherapy and chemotherapy.Many patients with soft tissue sarcomas are not diagnosed until it is too late,losing the surgical conditions and not being able to tolerate chemotherapy well,which seriously reduces the quality of life of the patients.With the development of molecular biology and the emergence of targeted drugs,the targeted drugs have significant advantages in the efficacy and safety of individualized treatments,which can significantly extend the progression-free survival of the patients and improve the quality of life.And they provide more treatment options for the patients with advanced soft tissue sarcomas who cannot tolerate surgery and chemotherapy.Currently,there are two types of commonly used targeted drugs for soft tissue sarcomas.One is a small molecule compound,including anrotinib,apatinib and pazopanil and the other is called monoclonal antibodies,such as bevacizumab and PD-1 antibodies.In this paper,we review the research progress of targeted drugs for soft tissue sarcomas.